论文部分内容阅读
为探讨血管内皮生长因子（VEGF）在喉癌中的作用及可能的作用方式，用抗VEGF抗体及其受体flt抗体通过微波处理暴露抗原后，进行标准化的EliteABC染色；将不同浓度的抗VEGF及抗flt抗体分别加入HEP－2细胞的培养液中，培养5d后测HEP－2细胞的活性（MTT法）。结果：免疫组化染色显示VEGF及其受体flt主要在喉癌细胞和血管内皮细胞表达；不同浓度的抗VEGF抗体及抗flt抗体对HEP－2细胞的生长均有抑制作用，在高浓度时存在剂量一效应关系。表明：喉癌细胞不仅可以合成分泌VEGF，喉癌细胞上同时还存在其受体flt，中和VEGF抗体及封闭VEGF的受体；flt对人喉癌HEP－2细胞的生长均有显著抑制作用。
To investigate the role of vascular endothelial growth factor (VEGF) in laryngeal squamous cell carcinoma and its possible mode of action, anti-VEGF antibody and its receptor flt antibody were exposed to the antigen by microwave treatment after normalized EliteABC staining; different concentrations of anti-VEGF And anti-flt antibody were added to the culture medium of HEP-2 cells respectively, and the activity of HEP-2 cells was measured 5 days after culturing (MTT method). Results: Immunohistochemical staining showed that VEGF and its receptor flt were mainly expressed in laryngeal carcinoma cells and vascular endothelial cells. Different concentrations of anti-VEGF antibody and anti-flt antibody could inhibit the growth of HEP-2 cells. At high concentration There is a dose-response relationship. The results showed that laryngeal cancer cells not only can synthesize and secrete VEGF, but also have receptors of flt, neutralizing VEGF and blocking VEGF on laryngeal cancer cells; flt also significantly inhibited the growth of human laryngeal carcinoma HEP-2 cells .